David Spellman

Keine laufenden Positionen mehr

Vermögen: - $ am 30.04.2024

48 Jahre

Health Technology

Consumer Services

Ehemalige bekannte Positionen von David Spellman

Unternehmen	Position	Beginn	Ende
AKEBIA THERAPEUTICS, INC.	Comptroller/Controller/Auditor	30.12.2022	23.06.2023
	Finanzdirektor/CFO	29.06.2020	23.06.2023
	Treasurer	29.06.2020	23.06.2023
Intarcia Therapeutics, Inc. Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.	Finanzdirektor/CFO	01.11.2019	29.06.2020
	Corporate Officer/Principal	01.06.2019	01.11.2019
MERSANA THERAPEUTICS, INC.	Finanzdirektor/CFO	12.03.2018	30.06.2019
VERTEX PHARMACEUTICALS INCORPORATED	Corporate Officer/Principal	-	-

The Wharton School of the University of Pennsylvania

Undergraduate Degree

International

Vereinigte Staaten

Operativ

Director of Finance/CFO	3
Corporate Officer/Principal	2
Undergraduate Degree	1

Sektoral

Health Technology	5
Consumer Services	2

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	3
MERSANA THERAPEUTICS, INC.	Health Technology
VERTEX PHARMACEUTICALS INCORPORATED	Health Technology
AKEBIA THERAPEUTICS, INC.	Health Technology

Private Unternehmen	1
Intarcia Therapeutics, Inc. Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.	Health Technology

Private Unternehmen

Health Technology